Acute Myeloid Leukemia Real World Treatment Patterns

Sponsor
Pfizer
Study ID
NCT04230564
Status
Withdrawn

Conditions

  • Leukemia, Myeloid, Acute

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • azacitidine — DRUG
    Patients taking azacitidine
  • venetoclax — DRUG
    patients taking venetoclax
  • glasdegib — DRUG
    patients taking glasdegib

Study Details

Among patients with a diagnosis of AML who received non-intensive chemotherapy: * Describe patient demographic and clinical characteristics * Describe treatment patterns * Describe effectiveness outcomes * Evaluate tumor response

Key Dates

Start date
Oct 31, 2020
Status verified
Feb 2021
Primary completion
Mar 31, 2021
Completion
Mar 31, 2021

Study Design

Enrollment
0 participants (actual)

Arms

  • Arm: AML
    Patients diagnosed with AML

Primary Outcome Measure

Overall Survival [ Time Frame: January 1, 2012 to January 10, 2020 ]

Related Studies